Perispinal Etanercept to improve Stroke Outcomes (PESTO) clinical trial
- Have you had a stroke (any type) between 1 and 15 years ago?
- Were you between the ages of 18 and 65 at the time of your stroke?
- Do you still have a moderate to severe disability following your stroke?
The Perispinal Etanercept to improve Stroke Outcomes (PESTO) clinical trial is actively recruiting participants in line with Government advice.
Funded by the Federal Government through the Medical Research Future Fund, this is Australia’s first multi-centred international clinical trial of perispinal etanercept in chronic stroke.
This trial seeks to determine if perispinal etanercept improves quality of life in working age survivors of stroke with a moderate to severe disability. It will also investigate if repeated treatments lead to improved quality of life compared to one treatment.
Australian sites are located in Melbourne, Victoria.
We understand that interstate travel is particularly challenging as the coronavirus pandemic continues to impact our community in 2021. The research team takes the time to ensure that anyone who is interested and eligible to participate makes an informed decision about their participation in the trial.
For queries and to find out more about participation in the trial, please email: email@example.com
PESTO trial information is listed on the Australian New Zealand Clinical Trials Registry.
The trial is led by Professor Vincent Thijs, The Florey Institute of Neuroscience and Mental Health.
Visit the PESTO Trial website at pestotrial.org